Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds

Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds

Thomas Wilke,1 Nils Picker,2 Sabrina Müller,2 Anna Stürmlinger,3 Barthold Deiters,4 Axel Dittmar,1 Jens Aberle,5 Maximilian Gabler3 1IPAM e.V., Wismar, Germany; 2Ingress-Health HWM GmbH, Wismar, Germany; 3Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany; 4GWQ ServicePlus AG, Düsseldo...

Full description

Bibliographic Details
Main Authors: Wilke T, Picker N, Müller S, Stürmlinger A, Deiters B, Dittmar A, Aberle J, Gabler M
Format: Article
Language:English
Published: Dove Medical Press 2022-05-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
type 2 diabetes mellitus
sodium-glucose cotransporter-2 inhibitor
dpp-4 inhibitors
glp-1 receptor agonists
healthcare costs
Online Access:https://www.dovepress.com/healthcare-resource-utilization-and-associated-costs-in-new-users-of-e-peer-reviewed-fulltext-article-CEOR

Internet

https://www.dovepress.com/healthcare-resource-utilization-and-associated-costs-in-new-users-of-e-peer-reviewed-fulltext-article-CEOR

Similar Items